Roivant Q3 net loss widens to $385M; VTAMA revenue $9.2M, RVT-3101 Phase 2b positive

Roivant Sciences Ltd.

2022-Q3 EPS reported -$1.39 revenue$33,904,000

Net loss of $384.9M ($0.49 per share) for Q3 FY2023, compared to net loss of $306.1M ($0.41) a year ago.
VTAMA net product revenue $9.2M; nearly 100,000 prescriptions written by ~8,600 prescribers since launch; 57% of commercial lives covered.
RVT-3101 Phase 2b TUSCANY-2: 31% clinical remission (p=0.01) and 40% endoscopic improvement (p=0.01) at expected Phase 3 dose; biomarker-positive patients achieved 40%/56% rates.
Completed $230M upsized equity offering; pro forma cash $1.9B, extending runway into 2H 2025.
Topline data expected from ADORING 1 (VTAMA in atopic dermatitis) in March 2023 and ADORING 2 in May 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Roivant Sciences Ltd. reported financial results for the third quarter ended December 31, 2022.

Period: the third quarter ended December 31, 2022
Result: reported results

Exact text from the filing

On February 13, 2023, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-23-006178

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.